Thirona

Executive Summary

Thirona is a Dutch medtech company that leverages AI for quantitative analysis of thoracic CT scans, primarily through its LungQ platform. Founded in 2014 and based in Nijmegen, the company automates the segmentation and quantification of lung structures to aid in the detection, measurement, and tracking of pulmonary diseases. Its technology supports precision medicine in respiratory care, serving pharmaceutical trials, clinical research, and minimally invasive interventions. By providing high-precision, reproducible data, Thirona enables more objective assessment of disease progression and treatment response, positioning itself as a key enabler in the respiratory diagnostic and drug development ecosystem. The platform's integration into clinical workflows holds promise for improving patient outcomes and accelerating the development of novel therapies. Thirona's AI-driven approach addresses significant unmet needs in pulmonary imaging, where manual quantification is time-consuming and variable. With a growing focus on personalized medicine and the increasing volume of thoracic CT scans, the company is well-positioned to capture market share. Its software-as-a-service model and partnerships with pharmaceutical companies for trial imaging provide recurring revenue streams. While Thirona operates in a competitive landscape, its niche specialization and regulatory experience (CE-marked) offer a competitive edge. The company's future growth hinges on expanding commercial partnerships, securing regulatory clearances in key markets, and demonstrating clinical utility through peer-reviewed publications. Overall, Thirona represents a promising investment opportunity in the AI diagnostics space with a clear value proposition in respiratory care.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnership with a top-10 pharmaceutical company for LungQ in respiratory clinical trials70% success
• Q1 2027FDA 510(k) clearance for LungQ in quantitative assessment of emphysema50% success
• Q4 2026Publication of a validation study in a high-impact journal demonstrating LungQ's superiority over manual quantification for ILD monitoring80% success